Adjuvant is required when using Env lipopeptide construct to induce HIV type 1-specific neutralizing antibody responses in mice in vivo

AIDS Research and Human Retroviruses

Volumn 14, Issue 10, 1998, Pages 901-909

  Sauzet, Jean Pierre ^a   Moog, Christiane ^b   Krivine, Anne ^c   Martinon, Frederic ^a   Bossus, Marc ^d   Gras Masse, Helene ^d   Tartar, Andre ^d   Guillet, Jean Gerard ^a   Gomard, Elisabeth ^a  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c HÔPITAL SAINT VINCENT DE PAUL   (France)

^d UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ARTICLE; DRUG FORMULATION; HOST RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOTHERAPY; INFECTION RESISTANCE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; VIRUS NEUTRALIZATION;

EID: 0032503932     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.901     Document Type: Article

References (41)

1. Germain RN and Margulies DU: The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993;11:403-450.
2. Takahashi H, Takeshita T, Morein B, Putney SD, Germain RN, and Berzofsky JA: Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature (London) 1990;334:873-875.
3. Lovgren K and Morein B: The ISCOM: An antigen delivery system with built-in adjuvant. Mol Immunol 1991;28:285-286.
4. Noguchi Y, Noguchi T, Sato T, et al.: Priming for in vitro and in vivo anti-human T lymphotropic virus type 1 cellular immunity by virus-related proteins reconstituted into liposomes. J Immunol 1991;146:3599-3603.
5. Collins DS, Findlay K, and Harding CV: Processing of exogenous liposome-encapsulated antigens in vivo generates class I MHC-restricted T cell responses. J Immunol 1992;148:3336-3341.
6. Reddy R, Zhou F, Nair S, Huang L, and Rouse BT: In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. J Immunol 1992;148:1585-1589.
7. Wu JY, Gardner BH, Murphy CI, et al.: Saponin enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J Immunol 1992;148:1519-1525.
8. Hancock GE, Speelamn DJ, Frenchick PJ, Mineo-Kuhn MM, Baggs RB, and Hahn DJ: Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in BALB/c mice that are similar to those generated by experimental infection. Vaccine 1995;13:391-400.
9. Raychaudhuri S, Tonks M, Carbone F, Ryskamp T, Morrow WJW, and Hanna N: Induction of antigen-specific class I-restricted cytotoxic T cells by soluble protein in vivo. Proc Natl Acad Sci USA 1992;89:8308-8312.
10. Griffin DE and Ward BJ: Differential CD4 T cell activation in measles. J Infect Dis 1993;168:275-281.
11. Clerici M and Shearer GM: A Th1 → Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
12. Barcellini W, Rizzardi GP, Borghi MO, Fain C, Lazzarin A, and Meroni PL: TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS 1994;8: 757-762.
13. Matthews TJ, Lyerly HK, Weinhold KJ, et al.: Prospects for development of a vaccine against HTLV-III-related disorders. AIDS Res Hum Retroviruses 1987;3:197-206.
14. Javaherian K, Langlois AJ, McDanal C, et al.: Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989;86:6768-6772.
15. Takahashi H, Cohen J, Hosmalin A, et al.: An immunodominant epitope of the HIV gp160 envelope glycoprotein recognized by class I MHC molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1988;85:3105-3109.
16. Takahashi H, Germain RN, Moss B, and Berzofsky JA: An immunodominant class-I restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class-II restricted help for itself. J Exp Med 1990;171:571-576.
17. Girard M, Kieny MP, Pinter A, et al.: Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88:542-546.
18. Wang CY, Looney DJ, Li ML, et al.: Long-term high-titer neutralizing activity induced by octameric synthetic HIV antigen. Science 1991;254:285-288.
19. Nardelli B, Lu Y-A, Shiu DR, Delpierre-Defoort C, Profy AT, and Tam JP: A chemically defined synthetic vaccine model for HIV-1. J Immunol 1992;148:914-920.
20. + cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc Natl Acad Sci USA 1991;88:9448-9452.
21. Defoort J-P, Nardelli B, Huang W, Ho DD, and Tam JP: Macromolecular assemblage in the design of a synthetic AIDS vaccine. Proc Natl Acad Sci USA 1992;89:3879-3883.
22. Martinon F, Gras-Masse H, Boutillon, C, et al.: Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant: Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J Immunol 1992;149:3416.
23. Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, and Berzofsky JA: Construction of an HIV-1 peptide vaccine containing a multi-determinant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. J Immunol 1993;150:5647-5665.
24. + CTL in vivo with peptide vaccine constructs. J Immunol 1994;152:549-557.
25. Ahlers JD, Dunlop N, Pendleton CD, Newman M, Nara PL, and Berzofsky JA: Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res Hum Retroviruses 1996;12: 259-272.
26. Nardelli B and Tam JP: Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigenic peptide. Immunology 1993;79:355-361.
27. Nardelli B, Haser PB, and Tam JP: Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses. Vaccine 1994; 12:1335-1339.
28. Sauzet JP, Deprez B, Martinon F, Guillet JG, Gras-Masse H, and Gomard E: Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides. Vaccine 1995;13:1339-1345.
29. Deprez B, Sauzet JP, Boutillon C, et al.: Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus specific CTL. Vaccine 1996;14:375-382.
30. Le-Nguyen D, Heitz A, and Castro B: Renin substrate. 2. Rapid solid phase peptide synthesis of the ratine sequence tetradecapeptide using BOP reagent. J Chem Soc Perkin Trans 1987;1: 1915-1916.
31. Hudson D: Methodological implication of simultaneous solid-phase peptide synthesis. 1. Comparison of different coupling procedures. J Org Chem 1988;53:617-624.
32. Moog C, Spenlehauer C, Fleury H, et al.: Neutralization of primary human immunodeficiency virus type 1 isolates: A study of parameters implicated in neutralization in vitro. AIDS Res Hum Retroviruses 1997;13:19-27.
33. Gupta RK and Siber GR: Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995;13:1263-1276.
34. Vitiello A, Ishioka G, Grey HM, et al.: Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995;95:341-349.
35. Powell MF, Eastman DJ, Lim A, et al.: Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs. AIDS Res Hum Retroviruses 1995;11:203-209.
36. VanCott TC, Mascola JR, Kaminski RW, et al.: Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol 1997;71:4319-4330.
37. Schirmbeck R, Melber K, Mertens T, and Reinmann J: Selective stimulation of murine cytotoxic T cell and antibody responses by paniculate or monomeric hepatitis B virus surface (S) antigen. Eur J Immunol 1994;24:1088-1096.
38. + cytotoxic T lymphocyte responses in vivo. J Immunol 1994;152:1110-1119.
39. Grun JL and Maurer PH: Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: The role of endogenous interleukin 1 in proliferative responses. Cell Immunol 1989;121:134-145.
40. Loing E, Delanoye A, Sergheraert C, Tartar A, and Gras-Masse H: Assessing delivery of lipopeptides into the cytoplasm of intact cells by a functional assay based on PKC inhibition. I. The Jurkat model. Peptide Res 1996;9:229-232.
41. Powell MF, Cleland JL, Eastman DJ, et al.: Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons. AIDS Res Hum Retroviruses 1994;10:S105-S108.